Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2017-N-2562

Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

Documents

Comments

Key Dates

Comment Period OpensJul 28, 2017

Documents

Type	Title	Posted	Comments	Status
Other	Supplement from Novo Nordisk Inc.	Jan 20, 2026	--

Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

Key Dates

Documents

Comment Statistics

Keywords